Gel forming ophthalmic compositions containing povidone iodine and steroids
The gel-forming ophthalmic composition with povidone-iodine and difluprednate, stabilized by deacetylated gellan gum, addresses antibiotic resistance and rapid drug elimination, offering sustained release and enhanced bioavailability for effective treatment of infectious keratoconjunctivitis.
WO2026128000A1 Publication Date: 2026-06-18IVIEW THERAPEUTICS INC
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- IVIEW THERAPEUTICS INC
- Filing Date
- 2025-04-21
- Publication Date
- 2026-06-18
AI Technical Summary
⚠Technical Problem
Current ophthalmic treatments for infectious keratoconjunctivitis face challenges such as antibiotic resistance, lack of targeted therapy for viral infections, and rapid drug elimination due to tear dilution, leading to reduced efficacy and patient compliance.
⚗Method used
A novel gel-forming ophthalmic composition combining povidone-iodine with next-generation steroids like difluprednate and an in-situ gel-forming system using deacetylated gellan gum to enhance stability, sustained drug release, and bioavailability.
🎯Benefits of technology
The composition provides broad-spectrum antimicrobial activity, prolonged drug retention, increased solubility, and improved bioavailability, addressing multiple infectious etiologies effectively while minimizing side effects.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure 1 Figure 2 
Figure 3
Abstract
The present invention provides a gel-forming ophthalmic composition comprising povidone iodine, a steroid, a polysaccharide polymer gelling agent, water, and suitable excipients for ophthalmic preparations. This composition is not only stable, but also can effectively kill a variety of pathogens, rapidly alleviate associated signs and symptoms, and treat ocular diseases.
Need to check novelty before this filing date? Find Prior Art